Michael C. Honigberg

Michael C. Honigberg

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Michael C. Honigberg

Mass General Brigham, Heart and Vascular Institute , Boston, MA 02114

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2019 in JAMA
Verified
Journal Article
Open access
PDF file
MHMichael C. Honigberg
Michael C. Honigberg
SZSeyedeh Maryam Zekavat
Seyedeh Maryam Zekavat
KAKrishna Aragam
Krishna Aragam
PFPhoebe Finneran
Phoebe Finneran
DKDerek Klarin
Derek Klarin
PNPradeep Natarajan
Pradeep Natarajan
Although cardiovascular disease is the leading cause of death among women in the United States and worldwide,1 sex-specific risk factors for cardiovascular disease in women remain under-recognized and incompletely understood.2 In studies of women who underwent menopause in the 1990s and 2000s, most women in Western countries experienced menopause between age 40 and 58 years, with mean age at menopause of 51 to 52 years.3,4 Up to 10% of women underwent menopause before age 45 years, and 1% experienced menopause before age 40 years.4-6 Premature menopause has been associated with increased risk of coronary artery disease (CAD) and, less consistently, with increased risk of stroke.7-10 Additionally, an analysis from the Women’s Health Initiative found a modest association between earlier menopausal age and increased risk of heart failure.11

18 October 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ANAbhishek Niroula
Abhishek Niroula
ASAswin Sekar
Aswin Sekar
MMMark A. Murakami
Mark A. Murakami
MTMark Trinder
Mark Trinder
MAMridul Agrawal
Mridul Agrawal
BEBenjamin L. Ebert
Benjamin L. Ebert

1 December 2019 in JACC
Verified
Journal Article
Closed access
MHMichael C. Honigberg
Michael C. Honigberg
SZSeyedeh Maryam Zekavat
Seyedeh Maryam Zekavat
KAKrishna Aragam
Krishna Aragam
DKDerek Klarin
Derek Klarin
DBDeepak L. Bhatt
Deepak L. Bhatt
PNPradeep Natarajan
Pradeep Natarajan

17 February 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
AOAnna C. O’kElly
Anna C. O’kElly
EMErin D. Michos
Erin D. Michos
CSChrisandra L. Shufelt
Chrisandra L. Shufelt
JVJane V. Vermunt
Jane V. Vermunt
MMMargo B. Minissian
Margo B. Minissian
MHMichael C. Honigberg
Michael C. Honigberg
Beyond conventional risk factors for cardiovascular disease, women face an additional burden of sex-specific risk factors. Key stages of a woman’s reproductive history may influence or reveal short- and long-term cardiometabolic and cardiovascular trajectories. Early and late menarche, polycystic ovary syndrome, infertility, adverse pregnancy outcomes (eg, hypertensive disorders of pregnancy, gestational diabetes, preterm delivery, and intrauterine growth restriction), and absence of breastfeeding are all associated with increased future cardiovascular disease risk. The menopause transition additionally represents a period of accelerated cardiovascular disease risk, with timing (eg, premature menopause), mechanism, and symptoms of menopause, as well as treatment of menopause symptoms, each contributing to this risk. Differences in conventional cardiovascular disease risk factors appear to explain some, but not all, of the observed associations between reproductive history and later-life cardiovascular disease; further research is needed to elucidate hormonal effects and unique sex-specific disease mechanisms. A history of reproductive risk factors represents an opportunity for comprehensive risk factor screening, refinement of cardiovascular disease risk assessment, and implementation of primordial and primary prevention to optimize long-term cardiometabolic health in women.

20 January 2022 in Blood
Verified
Journal Article
Open access
PDF file
PMPeter G. Miller
Peter G. Miller
DQDandi Qiao
Dandi Qiao
JRJoselyn Rojas
Joselyn Rojas
MHMichael C. Honigberg
Michael C. Honigberg
ASAdam S. Sperling
Adam S. Sperling
FCfor the COPDGene Study Investigators, National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium
for the COPDGene Study Investigators, National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium
Chronic obstructive pulmonary disease (COPD) is associated with age and smoking, but other determinants of the disease are incompletely understood. Clonal hematopoiesis of indeterminate potential (CHIP) is a common, age-related state in which somatic mutations in clonal blood populations induce aberrant inflammatory responses. Patients with CHIP have an elevated risk for cardiovascular disease, but the association of CHIP with COPD remains unclear. We analyzed whole-genome sequencing and whole-exome sequencing data to detect CHIP in 48 835 patients, of whom 8444 had moderate to very severe COPD, from four separate cohorts with COPD phenotyping and smoking history. We measured emphysema in murine models in which Tet2 was deleted in hematopoietic cells. In the COPDGene cohort, individuals with CHIP had risks of moderate-to-severe, severe, or very severe COPD that were 1.6 (adjusted 95% confidence interval [CI], 1.1-2.2) and 2.2 (adjusted 95% CI, 1.5-3.2) times greater than those for noncarriers. These findings were consistently observed in three additional cohorts and meta-analyses of all patients. CHIP was also associated with decreased FEV1% predicted in the COPDGene cohort (mean between-group differences, −5.7%; adjusted 95% CI, −8.8% to −2.6%), a finding replicated in additional cohorts. Smoke exposure was associated with a small but significant increased risk of having CHIP (odds ratio, 1.03 per 10 pack-years; 95% CI, 1.01-1.05 per 10 pack-years) in the meta-analysis of all patients. Inactivation of Tet2 in mouse hematopoietic cells exacerbated the development of emphysema and inflammation in models of cigarette smoke exposure. Somatic mutations in blood cells are associated with the development and severity of COPD, independent of age and cumulative smoke exposure.

11 January 2022 in Circulation
Verified
Journal Article
Open access
PDF file
SZSeyedeh Maryam Zekavat
Seyedeh Maryam Zekavat
VRVineet K. Raghu
Vineet K. Raghu
MTMark Trinder
Mark Trinder
YYYixuan Ye
Yixuan Ye
SKSatoshi Koyama
Satoshi Koyama
PNPradeep Natarajan
Pradeep Natarajan
Background: The microvasculature, the smallest blood vessels in the body, has key roles in maintenance of organ health and tumorigenesis. The retinal fundus is a window for human in vivo noninvasive assessment of the microvasculature. Large-scale complementary machine learning-based assessment of the retinal vasculature with phenome-wide and genome-wide analyses may yield new insights into human health and disease. Methods: We used 97 895 retinal fundus images from 54 813 UK Biobank participants. Using convolutional neural networks to segment the retinal microvasculature, we calculated vascular density and fractal dimension as a measure of vascular branching complexity. We associated these indices with 1866 incident International Classification of Diseases –based conditions (median 10-year follow-up) and 88 quantitative traits, adjusting for age, sex, smoking status, and ethnicity. Results: Low retinal vascular fractal dimension and density were significantly associated with higher risks for incident mortality, hypertension, congestive heart failure, renal failure, type 2 diabetes, sleep apnea, anemia, and multiple ocular conditions, as well as corresponding quantitative traits. Genome-wide association of vascular fractal dimension and density identified 7 and 13 novel loci, respectively, that were enriched for pathways linked to angiogenesis (eg, vascular endothelial growth factor, platelet-derived growth factor receptor, angiopoietin, and WNT signaling pathways) and inflammation (eg, interleukin, cytokine signaling). Conclusions: Our results indicate that the retinal vasculature may serve as a biomarker for future cardiometabolic and ocular disease and provide insights into genes and biological pathways influencing microvascular indices. Moreover, such a framework highlights how deep learning of images can quantify an interpretable phenotype for integration with electronic health record, biomarker, and genetic data to inform risk prediction and risk modification.